Moleculin Biotech, Inc. (NASDAQ:MBRX) Q2 2023 Earnings Call Transcript August 11, 2023 8:30 AM ET

Company Participants

Jenene Thomas - IR

Walter Klemp - Chairman & CEO

John Paul Waymack - Senior CMO

Jonathan Foster - EVP & CFO

Conference Call Participants

Jonathan Aschoff - ROTH MKM

Jeff Jones - Oppenheimer

Operator

Hello, and welcome to the Moleculin Biotech Quarterly Update Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.

It's now my pleasure to turn the call over to your host, Jenene Thomas, Investor Relations. Please go ahead, Jenene.

Jenene Thomas

Thank you, Kevin. Good morning, and welcome everyone. At this time, I would like to remind our listeners that remarks made during this webcast may state management's intentions, beliefs, expectations, or future projections. These are forward-looking statements and involve risks and uncertainties. Forward-looking statements on this call are made pursuant to the safe harbor provisions of the federal securities laws and are based on Moleculin’s current expectations and actual results could differ materially. As a result, you should not place undue reliance on any forward-looking statements. Some of the factors that could cause actual results to differ materially from these contemplated by such forward-looking statements are discussed in the periodic reports, Moleculin files with the Securities and Exchange Commission. These documents are available in the Investors section of the company's website and on the Securities and Exchange Commission's website. We encourage you to review these documents carefully.

Additionally, certain information contained in this webcast relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the company's own estimates and research. While the company believes these third-party sources to be reliable as of the date of this presentation, it does not independently verify and makes no representation as to the adequacy, fairness, accuracy or completeness of or that any independent source has verifying any information obtained from third party source. Any data discussed regarding clinical trials and progress are considered preliminary and subject to change.

Joining us on the call today from the Moleculin’s management team are Walter Klemp, Chairman and Chief Executive Officer; Dr. John Paul Waymack, Senior Chief Medical Officer; and Jonathan Foster, Executive Vice President and Chief Financial Officer.

I would now like to turn the call over to Mr. Klemp, Chairman and CEO. Wally, please proceed.

Walter Klemp

Thanks, Jenene, and thanks to everyone on today's call for your interest in Moleculin. We reiterated our commitment on our last two quarterly calls that 2023 would be our year of data. And now the data from our priority pipeline programs are coming into view. We've now completed the Phase 1B portion of our MB-106 trial. That's the AML trial in Europe studying the combination of Annamycin with Cytarabine or Ara-C. Importantly, that means we've now established our Phase 2 dose and have commenced Phase 2 recruitment.